MMP9 and hematocrit: The MMP-9 inhibitor minocycline reduced the risk of HT after tPA in animal models (126, 127), and the Minocycline to Improve Neurologic Outcome in Stroke (MINOS) human trials showed a decrease in plasma MMP-9 levels in patients treated with intravenous tPA (128, 129).